# US 8,278,280 B2 · Antagonists of the bradykinin B1 receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,280 B2
- Document ID: US8278280B2
- Status: Granted
- Kind: B2
- Application number: 12/082,219
- Filed: 2008-04-08
- Published: 2009-05-28
- Granted: 2012-10-02
- Earliest claimed: 2003-10-22
- Assignees: Amgen Inc.
- Inventors: Gordon Ng; Yue-Sheng Li; Colin V. Gegg; Benny C. Askew, Jr.; Thomas Storz; Yuelie Lu; Derin C. D'Amico; Mark A. Jarosinski; Chuan-Fa Liu; Qi Huang
- Web page: https://patentgrep.com/patent/US8278280B2

## CPC

- A61K 38/043: {Kallidins; Bradykinins; Related peptides}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/18: Kallidins; Bradykinins; Related peptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

## Claims

### Claim 1

A composition of matter of the formula:
F′—Rz, or a physiologically acceptable salt thereof, wherein:
F′ is a multivalent polyethylene glycol (PEG) of combined molecular mass of about 1,000 Daltons to 100,000 Daltons;
R is independently in each instance —(X1)—(Y1)n wherein R is covalently bound to F′;
X1 and Y1 are independently in each instance peptides of the formula -L1-P1 and -L2-P2, respectively;
L1 and L2 are independently in each instance absent or linkers;
n is 0;
Z is 2 to 8; and
P1 and P2 are independently in each instance peptide antagonists of the bradykinin B1 receptor comprising an amino acid sequence selected from SEQ ID NOS: 15-18, 23, 25, 26, 39-41, 43, 44, and 46-54.

### Claim 2 (depends on 1)

The composition of matter of claim 1, wherein L1 and L2 are each independently absent or a peptidyl linker having from 1 to 9 amino acid residues.

### Claim 3 (depends on 2)

The composition of matter of claim 2, wherein the peptidyl linker has an amino acid sequence selected from SEQ ID NO:61 to SEQ ID NO:65, inclusive.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a composition of matter according to claim 1, and at least one pharmaceutically acceptable diluent, excipient, or carrier.

### Claim 5 (depends on 1)

The composition of matter of claim 1 wherein Z is 4.

### Claim 6 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 15.

### Claim 7 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 16.

### Claim 8 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 17.

### Claim 9 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 18.

### Claim 10 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 23.

### Claim 11 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 25.

### Claim 12 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 26.

### Claim 13 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 43.

### Claim 14 (depends on 1)

The composition of matter of claim 1, wherein the amino acid sequence is SEQ ID NO: 47.
